AFG3L2
AFG3-like protein 2
Protein Summary
ATP-dependent protease which is essential for axonal and neuron development. In neurons, mediates degradation of SMDT1/EMRE before its assembly with the uniporter complex, limiting the availability of SMDT1/EMRE for MCU assembly and promoting efficient assembly of gatekeeper subunits with MCU (PubMed:27642048). Required for the maturation of paraplegin (SPG7) after its cleavage by mitochondrial-processing peptidase (MPP), converting it into a proteolytically active mature form (By similarity). This gene encodes a protein localized in mitochondria and closely related to paraplegin. The paraplegin gene is responsible for an autosomal recessive form of hereditary spastic paraplegia. This gene is a candidate gene for other hereditary spastic paraplegias or neurodegenerative disorders. [provided by RefSeq, Jul 2008]
- ENST00000269143
- ENSP00000269143
- ENSG00000141385
- SCA28
- SPAX5
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
co-expressed gene | 1 | ||
molecular function | 0.96 | ||
protein domain | 0.92 | ||
disease perturbation | 0.87 | ||
kinase perturbation | 0.84 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 70.61 (req: < 5)
Gene RIFs: 29 (req: <= 3)
Antibodies: 229 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 70.61 (req: >= 5)
Gene RIFs: 29 (req: > 3)
Antibodies: 229 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 21
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0